Algorae Pharmaceuticals Limited
ASX: 1AI
Advances in AI drug discovery and key alliances fuel a sharp turnaround.
(Source: TradingView) 3-Month Performance Profile of 1AI on a DTF compared to S&P/ASX 200 (XJO).
Algorae Pharmaceuticals delivered meaningful progress in FY25, with net losses narrowing sharply by 61.68% YoY and cash reserves standing at $2.32 million. The year was defined by
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
